Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03704662 · ClinicalTrials.gov registry record · NA

Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable or Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma

A NA study of Pancreatic Cancer, sponsored by Medical College of Wisconsin.

Recruiting
Registry status
NA
Development phase
102
Enrollment target
1
Study location

NCT03704662 is a NA study of Pancreatic Cancer that is actively recruiting participants, run by Medical College of Wisconsin. The registered enrollment target is 102 participants, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (74% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03704662, a NA study of Pancreatic Cancer, is actively recruiting participants, sponsored by Medical College of Wisconsin.

RECRUITING
Registry status
NA
Development phase
102 participants
Enrollment target
1
Study location

Study Summary

Patients are randomized into two arms. Arm A patients will receive Stereotactic Body Radiation Therapy (SBRT) and Arm B patients with receive conventional concurrent chemotherapy and radiation therapy.

Conditions Studied

Interventions

  • RADIATION Stereotactic Body Radiation Therapy
  • RADIATION Preoperative Fractionated Radiation Therapy and Chemotherapy

Study Locations (1)

Wisconsin

  • Froedtert Hospital & Medical College of Wisconsin - Milwaukee

Trial Details

FieldValue
Enrollment Target 102 participants
Start Date 2018-10-22
Est. Completion 2031-06-01
Phase NA

Sponsor

Medical College of Wisconsin

447 total trials

What the Registry Record Tells You About NCT03704662

The ClinicalTrials.gov registry entry for NCT03704662 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 102 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (74% lower). The listed sponsor is Medical College of Wisconsin, which has 447 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Pancreatic Cancer appearing as the primary indexed condition, and to 2 interventions - of which Stereotactic Body Radiation Therapy is the first listed.

NCT03704662 reports 1 study location spanning 1 distinct geographic area - top geographies include Wisconsin.

Frequently Asked Questions

What is clinical trial NCT03704662 about?

NCT03704662 is a clinical study titled "Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable or Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma". Patients are randomized into two arms. Arm A patients will receive Stereotactic Body Radiation Therapy (SBRT) and Arm B patients with receive conventional concurrent chemotherapy and radiation therapy.

What is the current status of trial NCT03704662?

This trial is currently recruiting. It is a NA study. The enrollment target is 102 participants. The study started on 2018-10-22. Estimated completion is 2031-06-01.

What conditions does trial NCT03704662 study?

This clinical trial studies the following conditions: Pancreatic Cancer.

What interventions are being tested in trial NCT03704662?

The interventions under investigation include: Stereotactic Body Radiation Therapy (RADIATION), Preoperative Fractionated Radiation Therapy and Chemotherapy (RADIATION).

Who is sponsoring clinical trial NCT03704662?

This trial is sponsored by Medical College of Wisconsin, which has 447 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03704662 being conducted?

This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Pancreatic Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.